Act now to meet global heart disease targets

November 24, 2020

Sophia Antipolis, 24 November 2020: Cardiovascular disease remains the leading cause of mortality in Europe, and World Health Organization (WHO) heart disease goals will not be achieved by 2025 unless urgent action is taken. That is the finding of a European Society of Cardiology (ESC) report published today.

"Cardiovascular Realities 2020" is a compendium of the latest statistics on cardiovascular disease (CVD) in Europe.1 The document provides numbers of people with heart conditions, death rates, and levels of risk factors including obesity, diabetes, and high blood pressure.

Comparisons of data over time show alarming trends which suggest it is unlikely that WHO noncommunicable disease (NCD) targets for global cardiovascular health will be met.2

Dr. Hans Henri Kluge, WHO Regional Director for Europe said: "We cannot be complacent. Healthcare disruption during the COVID-19 pandemic highlighted the importance of maintaining services to prevent and treat cardiovascular disease. Access to essential CVD medicines and technologies varies widely across Europe and more work is needed to achieve universal health coverage. I look forward to collaborating with European cardiologists and policymakers to tackle these issues."

In Europe, cardiovascular disease accounts for 47% and 39% of all deaths in women and men, respectively. The WHO has called for a 25% relative reduction in premature mortality from CVD by 2025 (compared to 2010). Today's report shows that in high-income countries, premature death from CVD (below age 70 years) has declined by 9% in women and 11% in men since 2010. But in middle-income countries, rates have fallen by just 8% in women and 2% in men, making it improbable that the target will be reached.

Major risk factors for CVD including obesity and diabetes are becoming more prevalent. More than one in five European adults are obese.3 The WHO has called for a halt to rises in both diabetes and obesity (between 2010 and 2025). However, from 2010 to 2016, the prevalence of obesity increased from 20.4% to 22.8% in women and from 19.2% to 22.3% in men - unless these trends are reversed, the goal will not be achieved.

Meanwhile, the median prevalence of diabetes increased from 3.2% in 2010 to 4.2% in 2015 - a rise of 28.5%. Middle-income countries suffered most: here the prevalence of diabetes increased by 37% (compared with 12.4% in high-income countries). These statistics make it unlikely that the WHO diabetes target will be met, particularly in middle-income countries.

High blood pressure is the leading global cause of premature death, accounting for almost 10 million deaths in 2015, of which 4.9 million were due to ischaemic heart disease and 3.5 million were due to stroke.4 The WHO target is a 25% relative reduction in high blood pressure between 2010 and 2025. The median prevalence of elevated blood pressure in Europe declined by 8.4% for women and by 5% for men in 2010 to 2015, making it unlikely that the target will be met unless these trends change.

Despite the immense burden of CVD, it does not receive the attention that decision-makers give to other diseases. This is why the ESC is calling for the development of national strategies covering all aspects of cardiovascular health: prevention, detection, treatment, and rehabilitation - this action is essential to meet the WHO's targets. Today's report enables local policymakers to take stock of their country's performance and identify areas demanding greater attention.

ESC President Professor Stephan Achenbach said: "Improvements in treatment and management of heart disease and stroke are being offset by a growing and ageing population, alongside worsening epidemics of obesity and type 2 diabetes. We must make sure that everyone has access to guideline-directed cardiovascular care and importantly, unhealthy lifestyles including poor diet and lack of physical activity must be addressed. Preventing an even greater burden of heart disease and stroke requires a major effort by a broad coalition of stakeholders: join us in the effort."
Authors: ESC Press Office
Tel: +33 (0)4 89 87 20 85
Mobile: +33 (0)7 8531 2036
Follow us on Twitter
Notes to editor


1 ESC Cardiovascular Realities 2020.

3 Obesity is defined as a body mass index (BMI) of 30 kg/m2 or higher.

4 Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

European Society of Cardiology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to